Aquestive Therapeutics (NASDAQ:AQST) Announces Quarterly Earnings Results

Aquestive Therapeutics (NASDAQ:AQST) posted its quarterly earnings data on Monday. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.07), Zacks reports. Aquestive Therapeutics updated its FY 2025 guidance to EPS.

Aquestive Therapeutics Stock Up 2.2%

NASDAQ:AQST traded up $0.06 during trading hours on Monday, reaching $2.85. 1,276,993 shares of the stock were exchanged, compared to its average volume of 1,452,195. Aquestive Therapeutics has a twelve month low of $2.20 and a twelve month high of $5.80. The business has a 50-day moving average of $2.78 and a two-hundred day moving average of $3.45. The company has a market capitalization of $283.06 million, a price-to-earnings ratio of -6.33 and a beta of 2.02.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Alliance Global Partners restated a “buy” rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a report on Wednesday, April 2nd. Raymond James set a $7.00 price objective on Aquestive Therapeutics in a report on Friday, March 7th. Finally, Lake Street Capital decreased their price objective on Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, March 7th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $10.67.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.